Increased Visceral Fat and Impaired Glucose Tolerance Predict the Increased Risk of Metabolic Syndrome in Japanese Middle-Aged Men

Abstract

Background: Impaired glucose tolerance (IGT) represents a stage of pre-diabetes and is a risk factor for future cardiovascular disease (CVD) which is a major cause of death in type 2 diabetes. The metabolic risk factors such as elevated blood pressure (elevated BP), abdominal obesity, dyslipidemia (elevated levels of total triglycerides [TG] and low levels of HDL cholesterol), and hyperglycemia precede the onset of the metabolic syndrome that increases the risk for CVD. This clustering is commonly associated with pre-diabetic hyperinsulinemia and it reflects peripheral insulin resistance. The present study documented that a visceral fat area (VFA) ≥ 100 cm² can replace waist-to-hip ratios (WHR) associated with IGT or IFG/IGT as a critical risk for the development of the metabolic syndrome in Japanese middle-aged men. Materials and Methods: A total of 575 middle-aged Japanese men with fasting plasma glucose levels of 6.1 - 6.9 mmol/l (impaired fasting glucose; IFG) were enrolled in the study. After a 75-g oral glucose tolerance test (OGTT), blood samples were collected 0 - 2 h later for determination of plasma glucose, insulin concentrations and other variables. Based on the results of an OGTT, the subjects were subgrouped into categories of glucose tolerance for further study. Results: Subjects with IGT or IFG/IGT had significantly higher levels of metabolic abnormalities such as high BMI, increased AUC glucose, elevated HbA1c, high VFA, elevated BP, and increased TG levels when compared to NGT (normal glucose tolerance) (p < 0.001). Compensatory hyper-secretion of insulin was seen in all pre-diabetic subjects, and was higher in IFG/IGT subjects (681 ± 33 pmol · h/l) than NGT (480 ± 22 pmol · h/l) (p < 0.01). The metabolic clustering including abnormal VFA, TG, HDL-C, and BP was strongly associated with the development of metabolic syndrome. Interestingly, VFA ≥ 100 cm² adjusted for the Japanese correlates strongly with the development of the metabolic syndrome in preclinical IGT or IFG/IGT subjects, with odds ratios of 2.7 and higher. Conclusion: VFA ≥ 100 cm² strongly correlates with prediabetic IGT or IFG/IGT which is possibly associated with underlying insulin resistance, and is a critical risk factor linked to the development of metabolic syndrome in Japanese middle-aged subjects with IGT or IFG/IGT.

Visceral fat - impaired glucose tolerance - metabolic syndrome - middle-aged men - Japanese

References

• 1 Alberti K G, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation.  Diabet Med. 1998;  15 539-553
• 2 Bloomgarden Z T. Cardiovascular disease and diabetes.  Diabetes Care. 2003;  230-237
• 3 Burchfiel C M, Hamman R F, Marshall J A, Baxter J, Kahn L B, Amirani J J. Cardiovascular risk factors and impaired glucose tolerance: the San Luis Valley Diabetes Study.  Am J Epidemiol. 1990;  131 57-70
• 4 Cassano P A, Segal M R, Vokonas P S, Weiss S T. Body fat distribution, blood pressure, and hypertension. A prospective cohort study of men in the normative aging study.  Ann Epidemiol. 1990;  1 33-48
• 5 DECODE Study Group . Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe.  Lancet. 1999;  354 617-621
• 6 The Examination Committee of Criteria for “Obesity Disease” in Japan . Novel criteria for “obesity disease” in Japan.  Circ J. 2002;  66 987-992
• 7 The Expert Committee . The Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus.  Diabetes Care. 1999;  22 S5-S19
• 8 Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults . Executive summary of the third report of the national cholesterol education, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).  JAMA. 2001;  285 2486-2497
• 9 Foster C, Rotimi C, Fraser H, Sundarum C, Liao Y, Gibson E, Holder Y, Hoyos M, Mellanson-King R. Hypertension, diabetes, and obesity in Barbados: findings from a recent population-based survey.  Ethn Dis. 1993;  3 404-412
• 10 Fuller J H, Shpley M J, Rose G, Jarrett R J, and Keen H C. Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall study.  Lancet. 1980;  1 1373-1376
• 11 Hanefeld M, Tamelkova-Kurktschiev T, Schaper F, Henkel E, Siegert G, Koehler C. Impaired fasting glucose is not a risk factor for atherosclerosis.  Diabet Med. 1999;  16 212-218
• 12 Hanson R L, Imperatore G, Bennett P H, Knowler W C. Components of the “metabolic syndrome” and incidence of type 2 diabetes.  Diabetes. 2002;  51 3120-3127
• 13 Jarrett R J, Keen H, Fuller J H, and McCartney P. Worsening of diabetes in men with impaired glucose tolerance.  Diabetologia. 1979;  16 25-30
• 14 Kashyap V S, Santamarina-Fojo S, Brown D R, Parrott C L, Applebaum-Bowden D, Meyn S, Talley G, Paigen B, Maeda N, Brewer Jr H B. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors.  J Clin Invest. 1995;  96 1612-1620
• 15 Lakka H M, Laaksonen D E, Lakka T A, Niskanen L K, Kumpusalo E, Tuomilehto J. et al . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.  JAMA. 2002;  288 2709-2716
• 16 Laakso M. Insulin resistance and coronary heart disease.  Curr Opin Lipidol. 1996;  7 217-226
• 17 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment - insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 18 Meigs J B. The metabolic syndrome.  BMJ. 2003;  327 61-62
• 19 Nakamura T, Tokunaga K, Shimomura I, Nishida M, Yoshida S, Kotani K, Islam A H, Keno Y, Kobatake T, Nagai Y. et al . Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men.  Atherosclerosis. 1994;  107 239-246
• 20 Reaven G M. Role of insulin resistance in human disease (syndrome X): an expanded definition.  Annu Rev Med. 1993;  44 121-131
• 21 Schoen R E, Thaete F L, Weissfeld J L, Sankey S S, Weissfeld J L, Kuller L H. Sagittal diameter in comparison with single slice CT as a predictor of total visceral adipose tissue volume.  Int J Obes Relat Metab Disord. 1998;  22 338-342
• 22 Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.  Diabetes Care. 1999;  22 920-924
• 23 Wajchenberg B L. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome.  Endocrine Rev. 2000;  21 697-738
• 24 Wareham N J, Phillip D I, Byrne C D. The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion.  Diabet Med. 1995;  12 931
• 25 Yoshizumi T, Nakamura T, Yamane M, Hasan A M, Islam W, Menju M, Yamasaki K. Abdominal fat: Standardized technique for measurement at CT.  Radiology. 1999;  211 283-286